AGIO — Agios Pharmaceuticals, Inc.

AGIOS Pharmaceuticals Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Revenue: Reported at $12.9 million for Q3 2025, a 44% increase year-over-year from $9 million in Q3 2024, and a slight increase of 3% from $12.5 million in Q2 2025.
• Cost of Sales: $1.7 million for the quarter.
• R&D Expenses: Increased to $86.8 million, up $14.3 million from Q3 2024, primarily due to higher clinical trial costs.
• SG&A Expenses: $41.3 million, an increase of $2.7 million year-over-year, reflecting investments for the potential launch of PYRUKYND in thalassemia.
• Cash Position: Approximately $1.3 billion in cash and investments, providing a strong foundation for future investments.

2. Strategic Updates and Business Highlights

• PYRUKYND: Positioned as a foundational PK activator with potential applications in PK deficiency, thalassemia, and sickle cell disease. The PDUFA date for thalassemia has been extended to December 7, 2025, allowing for enhanced engagement with the thalassemia community.
• Regulatory Approvals: Received approval for PYRUKYND in adults with thalassemia in Saudi Arabia and a positive CHMP opinion for marketing authorization in Europe.
• Pipeline Progress: Completed enrollment in the Phase IIb trial of Tebapivat for lower-risk myelodysplastic syndromes (MDS) and ongoing trials for AG-181 (phenylketonuria) and AG-236 (polycythemia vera).
• Commercial Strategy: Partnerships with NewBridge Pharmaceuticals and Avanzanite Bioscience to support global commercialization while retaining rights and minimizing capital investment.

3. Forward Guidance and Outlook

• Revenue Growth: Anticipated continued growth in PYRUKYND net revenue in Q4 2025, supported by an additional ordering week and ongoing focus on PK deficiency.
• Full-Year Outlook: Expecting robust revenue growth for 2025 compared to 2024, although starting from a relatively small base.
• Upcoming Milestones: Anticipating top-line results from the Phase III RISE UP trial for sickle cell disease by year-end.

4. Bad News, Challenges, or Points of Concern

• REMS Program: The FDA's request for a Risk Evaluation and Mitigation Strategy (REMS) for thalassemia may pose challenges, although management believes it will not significantly hinder prescribing.
• Market Access Delays: In Europe, post-approval pricing and reimbursement processes could take 12 to 18 months, delaying revenue realization.
• Safety Monitoring: Ongoing monitoring for hepatocellular injury associated with PYRUKYND remains a concern, although no new safety issues have been reported.

5. Notable Q&A Insights

• REMS Program Details: The specifics of the REMS program are still under review, with expectations for monitoring requirements to be included due to the risk of liver injury.
• External Business Development: Agios is actively seeking external assets to expand its pipeline, focusing on rare diseases with transformative potential, independent of the sickle cell data readout timeline.
• Market Demand: There is strong interest from clinicians in Saudi Arabia for PYRUKYND, although the approval process for individual patient access is lengthy.
• Commercial Strategy Adjustments: The company remains confident that REMS will not be a barrier to prescribing, based on feedback from healthcare providers familiar with similar programs.

Overall, Agios Pharmaceuticals is positioned for growth with a solid financial foundation and strategic focus on rare diseases, despite facing regulatory and market access challenges.